Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification

被引:25
|
作者
Jia, Shanshan [1 ]
Luo, Hua [2 ]
Liu, Xinkui [1 ]
Fan, Xiaotian [1 ]
Huang, Zhihong [1 ]
Lu, Shan [1 ]
Shen, Liangliang [1 ]
Guo, Siyu [1 ]
Liu, Yingying [1 ]
Wang, Zhenzhong [3 ,4 ]
Cao, Liang [3 ,4 ]
Cao, Zeyu [3 ,4 ]
Zhang, Xinzhuang [3 ,4 ]
Zhou, Wei [1 ]
Zhang, Jingyuan [1 ]
Li, Jialin [1 ]
Wu, Jiarui [1 ]
Xiao, Wei [3 ,4 ]
机构
[1] Beijing Univ Chinese Med, Sch Chinese Mat Medial, Dept Clin Chinese Pharm, 11 North Three Ring East Rd, Beijing 100102, Peoples R China
[2] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China
[3] State Key Lab New Tech Chinese Med Pharmaceut Pro, Lianyungang 222001, Jiangsu, Peoples R China
[4] Key Lab New Tech Res TCM Extract & Purificat, Lianyungang 222047, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Reduning injection; COVID-19; Network pharmacology; SARS-CoV-2; Molecular docking; Western blot; ACUTE LUNG INJURY; TRADITIONAL CHINESE MEDICINE; CYTOKINE STORM; KAPPA-B; TARGETS; INFLAMMATION; PREDICTION; CELLS;
D O I
10.1016/j.jep.2021.113871
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Reduning injection (RDNI) is a patented Traditional Chinese medicine that contains three Chinese herbal medicines, respectively are the dry aboveground part of Artemisia annua L., the flower of Lonicera japonica Thunb., and the fruit Gardenia jasminoides J.Ellis. RDNI has been recommended for treating Coronavirus Disease 2019 (COVID-19) in the ?New Coronavirus Pneumonia Diagnosis and Treatment Plan". Aim of the study: To elucidate and verify the underlying mechanisms of RDNI for the treatment of COVID-19. Methods: This study firstly performed anti-SARS-CoV-2 experiments in Vero E6 cells. Then, network pharmacology combined with molecular docking was adopted to explore the potential mechanisms of RDNI in the treatment for COVID-19. After that, western blot and a cytokine chip were used to validate the predictive results. Results: We concluded that half toxic concentration of drug CC50 (dilution ratio) = 1:1280, CC50 = 2.031 mg crude drugs/mL (0.047 mg solid content/mL) and half effective concentration of drug (EC50) (diluted multiples) = 1:25140.3, EC50 = 103.420 ?g crude drugs/mL (2.405 ?g solid content/mL). We found that RDNI can mainly regulate targets like carbonic anhydrases (CAs), matrix metallopeptidases (MMPs) and pathways like PI3K/AKT, MAPK, Forkhead box O s and T cell receptor signaling pathways to reduce lung damage. We verified that RDNI could effectively inhibit the overexpression of MAPKs, PKC and p65 nuclear factor-?B. The injection could also affect cytokine levels, reduce inflammation and display antipyretic activity. Conclusion: RDNI can regulate ACE2, Mpro and PLP in COVID-19. The underlying mechanisms of RDNI in the treatment for COVID-19 may be related to the modulation of the cytokine levels and inflammation and its antipyretic activity by regulating the expression of MAPKs, PKC and p65 nuclear factor NF-?B.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] A network pharmacology study of reduning injection for the treatment of coronavirus disease-19
    Wu, Jian
    Ruan, Dong-Dong
    Fu, Tong-Fei
    Yuan, Jun
    [J]. WORLD JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2020, 6 (02) : 180 - 187
  • [2] A Network Pharmacology Study of Reduning Injection for the Treatment of Coronavirus Disease-19
    Jian Wu
    Dong-Dong Ruan
    Tong-Fei Fu
    Jun Yuan
    [J]. World Journal of Traditional Chinese Medicine, 2020, 6 (02) : 180 - 187
  • [3] The Pharmacological Mechanism of Xiyanping Injection for the Treatment of Novel Coronavirus Pneumonia (COVID-19): Based on Network Pharmacology Strategy
    Xia, Liang-jing
    Zhang, Liang-ming
    Yang, Kun
    Chen, Tong
    Ye, Xian-wen
    Yan, Zi-jun
    [J]. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [4] Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification
    Li, Yuan
    Chu, Fuhao
    Li, Ping
    Johnson, Nadia
    Li, Tao
    Wang, Yan
    An, Rongxian
    Wu, Dantong
    Chen, Jiena
    Su, Zeqi
    Gu, Xiaohong
    Ding, Xia
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2021, 271
  • [5] The Mechanism of Chaiyin Particles in the Treatment of COVID-19 Based on Network Pharmacology and Experimental Verification
    Xiong, Lewen
    Liu, Yan
    Zhao, Hongwei
    Wang, Yang
    Sun, Ying
    Wang, Aiyuan
    Zhang, Longfei
    Zhang, Yongqing
    [J]. NATURAL PRODUCT COMMUNICATIONS, 2022, 17 (08)
  • [6] Citation Network Analysis of the Novel Coronavirus Disease 2019 (COVID-19)
    Martinez-Perez, Clara
    Alvarez-Peregrina, Cristina
    Villa-Collar, Cesar
    Sanchez-Tena, Miguel Angel
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (20) : 1 - 32
  • [7] Study on the mechanism of treating COVID-19 with Shenqi Wan based on network pharmacology
    Ye, Xian-wen
    Deng, Ya-ling
    Zhang, Xia
    Liu, Min-min
    Liu, Ying
    Xie, Ya-ting
    Wan, Quan
    Huang, Min
    Zhang, Tao
    Xi, Jia-he
    Zhang, Jin-lian
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2021, 47 (08) : 1279 - 1289
  • [8] The 2019 Novel Coronavirus Disease (COVID-19) and Neonates
    Damanabad, Zhilla Heydarpoor
    Valizadeh, Leila
    Yeghanedoost, Sadollah
    Roshangar, Fariborz
    [J]. ACTA FACULTATIS MEDICAE NAISSENSIS, 2021, 38 (01) : 18 - 26
  • [9] Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology
    Chen, Xiao
    Yin, Yun-Hong
    Zhang, Meng-Yu
    Liu, Jian-Yu
    Li, Rui
    Qu, Yi-Qing
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (16): : 2511 - 2530
  • [10] Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19)
    Dixon, Dave L.
    Van Tassell, Benjamin W.
    Vecchie, Alessandra
    Bonaventura, Aldo
    Talasaz, Azita H.
    Kakavand, Hessam
    D'Ascenzo, Fabrizio
    Perciaccante, Antonio
    Castagno, Davide
    Ammirati, Enrico
    Biondi-Zoccai, Giuseppe
    Stevens, Michael P.
    Abbate, Antonio
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 75 (05) : 359 - 367